Compound News and Research

RSS

Human immune system can help predict recurrence, overall breast cancer survival

A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.

4 Apr 2011

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

Bristol-Myers Squibb Company today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4, and complete early virologic response in genotypes 1 and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

4 Apr 2011

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.

4 Apr 2011

Pfizer to present new investigational compounds data against cancer at AACR meeting

Pfizer Oncology will present nearly 30 abstracts highlighting research in new and established pathways, including inhibition of Hedgehog signaling; dual inhibition of PI3K/mTOR; and cancer stem cell-based targets.

2 Apr 2011

Sunshine Biopharma to present new Adva-27a data against cancer at AACR meeting

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that they will be presenting scientific data at the American Association for Cancer Research Meeting April 2-6, 2011 in Orlando Florida.

2 Apr 2011

Champions enters exclusive license agreement with BCCA for Irinophore C

Champions Biotechnology, Inc. announced today that it has exercised an option to license Irinophore C, a liposomal formulation of Irinotecan, from the BC Cancer Agency in British Columbia, Canada.

2 Apr 2011

Maple syrup contains a range of antioxidant compounds not found in other sweeteners

There's more good news about pure maple syrup from the University of Rhode Island (URI). Researchers there have now identified 54 compounds in maple syrup from Canada, double the amount previously reported, and many with antioxidant activity and potential health benefits. In laboratory studies, they acted as anti-cancer and anti-inflammatory agents. Initial studies also suggest that maple compounds may inhibit enzymes relevant in Type 2 diabetes management.

1 Apr 2011

Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s

Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.

31 Mar 2011

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.

31 Mar 2011

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

31 Mar 2011

SMFM praises FDA's announcement on Makena drug

The Society for Maternal-Fetal Medicine weighed in on today's FDA announcement to continue to allow pharmacies to compound hydroxyprogesterone caproate, also known as 17P.

31 Mar 2011

Basic Yellow 1 dye extends lifespan in healthy nematodes, slows Alzheimer's disease-like pathology in worms

Basic Yellow 1, a dye used in neuroscience laboratories around the world to detect damaged protein in Alzheimer's disease, is a wonder drug for nematode worms. In a study appearing in the March 30, online edition of Nature, the dye, also known as Thioflavin T, (ThT) extended lifespan in healthy nematode worms by more than 50 percent and slowed the disease process in worms bred to mimic aspects of Alzheimer's.

31 Mar 2011

Thirty four new beneficial compounds found in pure maple syrup

University of Rhode Island researcher Navindra Seeram has discovered 34 new beneficial compounds in pure maple syrup and confirmed that 20 compounds discovered last year in preliminary research play a key role in human health.

31 Mar 2011

Amyloid plaques in normal older individuals may be early signs of Alzheimer's

Researchers using two brain-imaging technologies have found that apparently normal older individuals with brain deposits of amyloid beta - the primary constituent of the plaques found in the brains of Alzheimer's disease patients - also had changes in brain structure similar to those seen in Alzheimer's patients.

31 Mar 2011

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-5902 during a poster session at the American Association for Cancer Research 102nd Annual Meeting being held in Orlando, Florida, April 2-6, 2011, at the Orange County Convention Center.

31 Mar 2011

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Metabolic Solutions Development Company, a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.

30 Mar 2011

SpHb sensor can monitor blood hemoglobin levels during spine surgery

A spectrophotometric hemoglobin sensor may become a useful new approach to noninvasive monitoring of blood hemoglobin levels during surgery, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Mar 2011

Dementia & Alzheimer’s drug trial with sleep hormone melatonin

A new drug is in the making that could improve the quality of life for people with dementia. Glasgow-based medical research company CPS Research is conducting a clinical trial using a drug containing the sleep hormone melatonin, which it is hoped will reduce the symptoms associated with the illness.

28 Mar 2011

PHOENIX phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB

The PHOENIX trial is a European, placebo-controlled, Phase III study treating catecholamine-resistant patients in distributive shock with the Nitric Oxide (NO) scavenger Pyridoxalated Haemoglobin Polyoxyethylene Conjugate (PHP). The study was launched by Curacyte AG in Austria, Belgium, Germany, Spain, The Netherlands and in the United Kingdom in 2009.

28 Mar 2011

Almac, BioFocus partner to provide FLT assays

BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac's FLEXYTETM fluorescence lifetime assays.

28 Mar 2011

Compound News and Research

Human immune system can help predict recurrence, overall breast cancer survival

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Pfizer to present new investigational compounds data against cancer at AACR meeting

Sunshine Biopharma to present new Adva-27a data against cancer at AACR meeting

Champions enters exclusive license agreement with BCCA for Irinophore C

Maple syrup contains a range of antioxidant compounds not found in other sweeteners

Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

RXi Pharmaceuticals to acquire Apthera

SMFM praises FDA's announcement on Makena drug

Basic Yellow 1 dye extends lifespan in healthy nematodes, slows Alzheimer's disease-like pathology in worms

Thirty four new beneficial compounds found in pure maple syrup

Amyloid plaques in normal older individuals may be early signs of Alzheimer's

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

SpHb sensor can monitor blood hemoglobin levels during spine surgery

Dementia & Alzheimer’s drug trial with sleep hormone melatonin

PHOENIX phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB

Almac, BioFocus partner to provide FLT assays

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News